Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience
Open Access
- 1 May 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (5) , 2223-2224
- https://doi.org/10.1128/aac.00240-09
Abstract
We read with great interest the review by Andes et al. ([1][1]) describing antifungal therapeutic drug monitoring (TDM). We agree that there are limited data suggesting serum posaconazole concentrations predict the efficacy of prophylaxis or treatment with this agent. Prior studies have reportedThis publication has 8 references indexed in Scilit:
- Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Antifungal Therapeutic Drug Monitoring: Established and Emerging IndicationsAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled TrialClinical Infectious Diseases, 2007
- Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal InfectionAntimicrobial Agents and Chemotherapy, 2006